Related Experiment Video

Updated: Aug 6, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Perspectives for cancer therapies with cdk2 inhibitors

S Wadler1

  • 1Division of Hematology/Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA. scw2004@med.cornell.edu

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|May 29, 2002
PubMed

Insights

Targeting Cyclin-dependent kinase 2 (Cdk2) offers a promising strategy for cancer therapy by inhibiting tumor cell proliferation. While current inhibitors show activity, developing more specific Cdk2 agents is crucial for effective cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Modern cancer treatments aim for molecular targets to minimize damage to healthy tissues.
  • Cyclin-dependent kinase 2 (Cdk2) is a key regulator of the cell cycle and a potential therapeutic target in cancer.
  • Cdk2's role in cell cycle progression (G1/S and S/G2 transitions) makes it critical for tumor growth.

Purpose of the Study:

  • To evaluate the therapeutic potential of targeting Cyclin-dependent kinase 2 (Cdk2) in cancer treatment.
  • To discuss the limitations of current non-specific cyclin-dependent kinase inhibitors.
  • To highlight the need for developing specific Cdk2 inhibitors.

Main Methods:

  • Review of Cdk2's role in cell cycle regulation and cancer.
  • Analysis of existing cyclin-dependent kinase inhibitors (e.g., flavopiridol, UCN-01).
  • Discussion of preclinical development of specific Cdk2 inhibitors.

Main Results:

  • Cdk2 is essential for the G1 to S phase transition via retinoblastoma protein (pRb) phosphorylation.
  • Inhibition of Cdk2 can lead to cytostasis and apoptosis in cancer cells.
  • Current clinical inhibitors like flavopiridol and UCN-01 lack Cdk2 specificity.

Conclusions:

  • Targeting Cdk2 is a viable strategy for developing novel anticancer therapies.
  • Specific Cdk2 inhibitors are in preclinical development and warrant further investigation.
  • Further research is needed to explore the therapeutic efficacy of specific Cdk2 inhibitors in human tumors.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...